Adicet Bio Revenue

Revenue

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

143

Market Cap

63.45M GBP

Revenue Chart

* This company reports financials in USD.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	-	-	-
Dec 31, 2022	24.99M	15.26M	156.83%
Dec 31, 2021	9.73M	-8.17M	-45.65%
Dec 31, 2020	17.90M	16.91M	1,699.30%
Dec 31, 2019	995.00K	-7.19M	-87.84%
Dec 31, 2018	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
AstraZeneca	43.19B
GSK plc	31.38B
Haleon	11.24B
Smith & Nephew	4.46B
Hikma Pharmaceuticals	2.39B
ConvaTec Group	1.74B
HUTCHMED (China)	483.31M
Genus	668.80M

Revenue Rankings

Adicet Bio News

18 days ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Business Wire
22 days ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
25 days ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - Business Wire
6 weeks ago - Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - Business Wire
7 weeks ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
2 months ago - Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire
2 months ago - Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer - Business Wire
3 months ago - Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma - Business Wire

More News